Asensus Surgical (Asensus Surgical) Cash per Share : $0.03 (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is Asensus Surgical Cash per Share?

Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities divided by Shares Outstanding (EOP). Asensus Surgical's Cash per Share for the quarter that ended in Mar. 2024 was $0.03.

Asensus Surgical Cash per Share Historical Data

The historical data trend for Asensus Surgical's Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Asensus Surgical Cash per Share Chart

Asensus Surgical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash per Share

Get a 7-Day Free Trial

0.46

0.14

0.42

0.30

0.08

Asensus Surgical Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash per Share	Get a 7-Day Free Trial															0.24	0.17	0.13	0.08	0.03

Asensus Surgical Cash per Share Calculation

This is the ratio of a company's available cash, including easy to liquidate short-term investment, to its total number of shares outstanding. The result indicates the percentage of a company's share price that is available to spend on company's activities, such as strengthening the business, paying down the debt and making dividend payment to shareholders. It's a reliable indicator of a company's financial health.

Asensus Surgical's Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	21.067	/	264.92
	=	0.08

Asensus Surgical's Cash per Share for the quarter that ended in Mar. 2024 is calculated as:

Cash per Share	=	Cash, Cash Equivalents, Marketable Securities	/	Shares Outstanding (EOP)
	=	7.989	/	271.99
	=	0.03

Asensus Surgical (AMEX:ASXC) Cash per Share Explanation

Cash per Share represents the liquidity of a compant's assets. A high level of Cash per Share suggests that there's enough money on hand for a company to cover any emergencies and that the company has adequate money to reinvest its business or pay dividends to investors. However, if the ratio is too high, it can also suggeust the inefficiency of management for not making a full usage of the cash.

Asensus Surgical Cash per Share Related Terms

Thank you for viewing the detailed overview of Asensus Surgical's Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Asensus Surgical (Asensus Surgical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Asensus Surgical Inc (AMEX:ASXC) » Definitions » Cash per Share

Comparable Companies

Traded in Other Exchanges

2TX:Germany

Address

1 TW Alexander Drive, Suite 160, Durham, NC, USA, 27703

Website

https://www.asensus.com

Asensus Surgical Inc is a medical device company that digitizes the interface between the surgeon and the patient to improve minimally invasive surgery through digital laparoscopy. It enables the use of advanced capabilities such as augmented intelligence, connectivity, and robotics in laparoscopy and seeks to address the current clinical, cognitive, and economic shortcomings in surgery. The Senhance Surgical System is the first machine vision system for use in robotic surgery, which is powered by the new Intelligent Surgical Unit that enables augmented intelligence in surgery and brings the benefits of digital laparoscopy to patients around the world. The company's single segment includes the research, development, and sale of medical device robotics to improve minimally invasive surgery.

Executives

Starling William N Jr	director	2300 BUCKSKIN ROAD, POCATELLO ID 83201
Andrea Biffi	director	C/O SOFAR SPA, VIA FIRENZE 40, TREZZANO ROSA (MI) L6 20060
Elizabeth Kwo	director	C/O FLEXION THERAPEUTICS, INC., 10 MALL ROAD, SUITE 301, BURLINGTON MA 01803
David Bruce Milne	director	ONE BOSTON PLACE, 201 WASHINGTON STREET, SUITE 3900, BOSTON MA 02108
Kevin J Hobert	director	343 STATE STREET, ROCHESTER NY 14650
Fernando Anthony C. J.	officer: Chief Technology Officer	635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Rampertab Shameze	officer: EVP, Chief Financial Officer	C/O ZOMEDICA PHARMACEUTICALS CORP., 3928 VARSITY DRIVE, ANN ARBOR MI 48108
Brett Farabaugh	officer: Interim CFO	108 T.W. ALEXANDER DRIVE, RESEARCH TRIANGLE PARK NC 27709
Joseph P Slattery	officer: EVP and CFO	C/O TRANSENTERIX, INC., 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27560
Eric A Smith	officer: Chief Commercial Officer	7 CALEB CIRCLE, SAN ANTONIO TX 78258
Todd Pope	director, officer: President and CEO	C/O TRANSENTERIX, 635 DAVIS DRIVE, SUITE 300, MORRISVILLE NC 27713
Willam N Kelley	director	MERCK & CO., INC., ONE MERCK DRIVE, WHITEHOUSE STATION X1 08889
Pfenniger Richard C Jr	director	4400 BISCAYNE BLVD., MIAMI FL 33137
Sofar, S.p.a	10 percent owner	VIA FIRENZE 40, TREZZANO ROSA L6 20060
Andrew N Schiff	director, 10 percent owner	PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022